55 results about "Pain therapy" patented technology

A fully automated computer controlled system is provided for adjustment of neurostimulation implants used in pain therapy and in treating neurological dysfunction which includes a patient interactive computer, and a universal transmitter interface integrally embedded in the patient interactive computer or built into the antenna which is capable of stimulating any type of implanted neurostimulation devices by imitating programming codes. The patient interacts with the system through the patient interactive computer. The universal transmitter interface includes a direct digital synthesizer, a transistor circuitry driving the antenna in ON-OFF fashion and a gating unit for driving the transistor circuitry under control of the processing means in the patient-interactive computer. Alternatively, the universal transmitting interface includes a balanced modulator for modulation of the carrier signal generated at the direct digital synthesizer.

Antisense oligodeoxynucleotides against VR1, corresponding nucleotide constructs, cells containing said nucleotide constructs, pharmaceutical and diagnostic substances, uses thereof in pain therapy, and methods for diagnosing symptoms related to VR1 and for identifying pain-modulating substances.

The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer-linker conjugates of the present invention may further comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy.

A wearable energy delivery system can be integrated with a wearable item to provide therapy to the user, including pain therapy, healing therapy, and muscle stimulation. Integration of the energy delivery system with apparel provides convenience to the user and allows hands free use of the system, which can be used during exercise or normal wear.

The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer-linker conjugates of the present invention may further comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy.

An energy delivery device for emitting a combination of different types of energy. The device can emit pulsed electromagnetic fields (PEMF) energy and another type of energy, including pulsed electrical energy, heat energy, vibration, percussion, etc. The combined energy can provide both healing and pain therapy as well as therapy to shallow as well as deeper tissue.

Provided are pharmaceutical compositions and methods for the alleviation of pain in a patient with optimal ratios of morphine and oxycodone that provide superior analgesic efficacy and lower incidence of adverse side effects compared to morphine and oxycodone alone. The pharmaceutical compositions comprise morphine and oxycodone, or pharmaceutically acceptable salts thereof, in ratios of about 3 to 2 to about 1 to 2, morphine to oxycodone by weight.

The present invention relates to the use of IκB-kinase Inhibitors and methods for the prophylaxis and therapy for treating pain comprising administering such compounds.

The invention provides methods and compositions for inhibiting opioid tolerance by administering an A₃AR agonist to a subject receiving opiate therapy for nociceptive pain. Also provided are methods of treating opiate withdrawal using an A₃AR agonist.

The present invention relates to novel methods of synthesis and isolation of dendrimer systems. In particular, the present invention is directed to novel dendrimer conjugates with defined and limited numbers of ligand conjugates and high levels of structural uniformity, methods of synthesizing the same, compositions comprising the conjugates, as well systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)).

Pellets containing an analgesic uniformly dispersed in a lipid carrier such as cholesterol mixed with fatty acid esters, can be used to provide long term pain relief. 5 mg cholesterol-tryglyceride-buprenorphine pellets released the majority of drug in 24-48 hours after implant and provide clinically significant plasma levels of analgesia in mice for 3-9 days. Blood levels of analgesia peak at day-1 and are substantially complete by day-5 depending on the level of buprenorphine. These results demonstrate that post surgical implants provide clinically significant levels of analgesia in the 24-48 hour period following surgery and thus obviate the time consuming, expensive, and high-risk need to inject mice post surgery. The pellets are safe and easy to use. Placed in the surgical wound at the end of surgery, they provide 2-3 days of analgesia and obviate the need for subsequent handling of the animal for pain therapy. The implants have no detectable effect on mouse behavior, hematology, or liver chemistry. The unexpected release kinetics of the 5 mg pellet provides an ideal implant for post surgical analgesia. These implants solve a significant problem facing scientists who use rodents in research and abide by international of animal welfare.

The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid in pain therapy.

The invention provides a pain therapy cream comprising an anhydrous topical delivery formulation for percutaneous absorption comprising an anhydrous carrier medium, a chemical exfoliant, a penetration enhancer, and one or more pain killing agent selected from the group consisting of an analgesic, anesthetic, anti-inflammatory, or antipruritic agent, a phytochemical and other painkilling active ingredients, and methods of using the pain therapy cream.

The present invention pertains to a non-invasive method and apparatus for predicting or monitoring analgesia and blood levels of opioid drugs in a patient receiving pain treatment, e.g., during palliative treatment. The inventive method comprises the measurement of one or more, preferably two or more, surrogate markers of a patient. According to the present invention surrogate markers correlate with the level of analgesia in the opioid receiving subject and thus provide a non-invasive method to predict and monitor analgesia during a treatment. Even more, surrogate markers were identified which correlate with the blood-concentration of the opioid in the subject. Thus, the invention provides a valuable clinical tool to assess and control pain treatments with opioids. Disclosed is the prediction method, an apparatus suitable for performing the inventive methods as well as the apparatus for use in medical treatments, such as pain therapy.

The disclosure provides methods and compositions for inhibiting pain by administering a GPR160 antagonist to a subject in need thereof. Also provided are methods of using GPR160 antagonists in combination with other pain therapies.

The invention provides an expression cassette comprising a DNA sequence encoding amino acids 1-99 of human preproenkephalin, a DNA sequence encoding a precursor of a carboxy-amidated peptide flanked by dibasic cleavage sites and optionally a DNA sequence encoding a marker protein (such as Enhanced Green Fluorescent Protein (GFP)) all in operable linkage and under control of a promoter. Where the encoded precursor of a carboxy-amidated peptide is an agonist for an opioid receptor, the invention further provides a method of treating neuropathic pain by administering the gene transfer vector comprising such an expression cassette to a patient. The invention also provides a method for detecting a peptide having a desired effect comprising introducing a library of DNA sequences encoding one or more precursors of carboxy-amidated peptides into host cells; expressing the carboxy-amidated peptides encoded in the library to provide expression products; and screening from the polypeptide expression products for the desired effect.

Device and method for improving the effectiveness of osteopathic pain therapy by monitoring one or more pharmacokinetic parameters of the subject with a point-of-care device after pain drug administration. In one embodiment, the pain drug is celecoxib and the pharmacokinetic parameter is AUC.

The invention discloses an impedance match-type optical power control circuit of a semiconductor laser pain therapy instrument, which comprises an optical power signal acquisition circuit, a trigger impedance conversion circuit and an amplification isolation circuit. The optical power signal acquisition circuit acquires laser power signals emitted by a laser, subtraction by an operational amplifier is carried out, voltage difference information is outputted, and trigger signals of a thyristor in the trigger impedance conversion circuit are triggered; when the voltage difference signals after clamping voltage stabilization are higher than 3.5 V, the resistance of the impedance conversion circuit formed by inductors L2 and L3 and capacitors C3 and C4 is increased, the impedance conversion circuit is then parallelly connected with a resistor RA and is then serially connected onto a resonant circuit formed by an inductor L4, a capacitor C5, a resistor R11 and a diode D3 for further impedance match, determined resistance is acquired and outputted as input resistor of an inverting input end of an operational amplifier AR2 in the amplification isolation circuit, after proportional amplification/buffer isolation, stable boosted power supply voltage VCC is provided for the laser, the power of light emitted by the laser LD1 is ensured to be constant, and therapy effects are achieved.

This invention discloses a bonesetting pain relieving plaster applied to therapy and a preparation method of the bonesetting pain therapy herb plaster. The bonesetting pain therapy herb plaster is prepared from the raw materials by weight as follows: 10 g of scorpion, 8 g of semen strychni, 17 g of suberect spatholobus stem, 12 g of safflower, 12 g of common monkshood mother root, 14 g of Chinese clematis root, 15 g of pubescent angelica root, 11 g of psoralea corylifolia, 10 g of chili, 17 g of rhizoma Chuanxiong, 13 g of dahurian angelica root, 3 g of pangolin, 6 g of dragon's blood, 10 g of centipede, 16 g of frankincense, 16 g of myrrh, 12 g of cape jasmine fruit, 10 g of himalayan teasel root, 10 g of Common Clubmoss herb, 8 g of cassia twig, 8 g of borneol, 5 g of camphor, 5 g of menthol, 5 g of azone, 200 g of Plumbum Rubrum and 500 g of sesame oil. The plaster can dispel wind and dampness, ease joint movement, relieve swelling and pain, promote blood circulation and remove stasis; meanwhile, with a traditional Chinese medicine transdermal absorption technology, osteoproliferation can be inhibited, bone and tissue repair is promoted, the plaster is a pure traditional Chinese medicine preparation, and has no toxic or side effects, the recurrence rate after healing is quite low, and the curative effect is obvious.